Company Analysis China Resources Pharmaceutical Group Limited
1. Summary
Advantages
- The company's current efficiency (ROE=8.07%) is higher than the sector average (ROE=4.42%)
Disadvantages
- Price (5.61 HK$) is higher than fair price (5.48 HK$)
- Dividends (4.32%) are below the sector average (5.7%).
- The stock's return over the last year (7.68%) is lower than the sector average (20.13%).
- Current debt level 25.59% has increased over 5 years from 18.76%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
China Resources Pharmaceutical Group Limited | Healthcare | Index | |
---|---|---|---|
7 days | 3.9% | 8.2% | -3.1% |
90 days | 2.7% | 23.9% | 16.4% |
1 year | 7.7% | 20.1% | 35% |
3320 vs Sector: China Resources Pharmaceutical Group Limited has significantly underperformed the "Healthcare" sector by -12.46% over the past year.
3320 vs Market: China Resources Pharmaceutical Group Limited has significantly underperformed the market by -27.28% over the past year.
Stable price: 3320 is not significantly more volatile than the rest of the market on "Hong Kong Exchanges" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 3320 with weekly volatility of 0.1476% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (5.61 HK$) is higher than the fair price (5.48 HK$).
Price is higher than fair: The current price (5.61 HK$) is 2.3% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (7.19) is lower than that of the sector as a whole (36.59).
P/E vs Market: The company's P/E (7.19) is lower than that of the market as a whole (26.8).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.2982) is lower than that of the sector as a whole (3.66).
P/BV vs Market: The company's P/BV (0.2982) is higher than that of the market as a whole (-11.95).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0.1133) is lower than that of the sector as a whole (7.13).
P/S vs Market: The company's P/S indicator (0.1133) is lower than that of the market as a whole (2.7).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (4.65) is higher than that of the sector as a whole (2.91).
EV/Ebitda vs Market: The company's EV/Ebitda (4.65) is lower than that of the market as a whole (9.94).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 3.38% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (3.38%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (83.09%).
5.4. ROE
ROE vs Sector: The company's ROE (8.07%) is higher than that of the sector as a whole (4.42%).
ROE vs Market: The company's ROE (8.07%) is higher than that of the market as a whole (5.98%).
5.5. ROA
ROA vs Sector: The company's ROA (1.58%) is lower than that of the sector as a whole (2.95%).
ROA vs Market: The company's ROA (1.58%) is lower than that of the market as a whole (3.18%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 4.32% is below the average for the sector '5.7%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 4.32% has been steadily paid over the past 7 years, DSI=0.93.
Weak dividend growth: The company's dividend yield 4.32% has been growing weakly or stagnant over the past 5 years. Growth over only 3 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (22.83%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription